ABSTRACT
INTRODUCTION
Prostate cancer is the second most common cancer in men, and the fourth overall. It is estimated that there were 1.1 million men in 2012 worldwide, accounting for 15% of the cancers diagnoses in men. 1 It is well known that prostate cancer is caused by various factors, including environmental and genetic factors. [2] [3] [4] Previous studies showed that genetic polymorphisms in DNA repair genes can lead to differential capacity to repair DNA damage, which may cause genetic instability and carcinogenesis. 5 In mammalian cells four different DNA repair mechanisms have been identified: base excision repair (BER), nucleotide excision repair (NER), double-strand break repair and mismatch repair. 6, 7 These DNA repair pathways can influence the maintenance of genomic integrity and modulation of repair capacity in response to DNA damage and thus susceptibility to cancers. 8 XRCC1 (X-ray repair cross-complementing group1) gene is located on chromosome 19q13.2 which codes for a 633 amino acid residue protein that acts as scaffolding protein. XRCC1 protein functions in a complex with many other components to facilitate BER and single-strand break-repair processes. 9 Several SNPs in XRCC1 have been identified, all of which affect the coding region of XRCC1. These coding polymorphisms were detected at codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) in different cancers including prostate cancer, but the results are inconsistent. [10] [11] [12] [13] These non-conservative amino acid changes may alter XRCC1 function and may have an impact on individual susceptibility to prostate cancer. Therefore, in this study, we conducted a casecontrol study to examine the role of XRCC1 codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) polymorphisms in the risk of prostate cancer.
METHODS

Patients:
This study included 572 consecutive primary prostate cancer patients. All the prostate cancer patients were newly diagnosed and histopathologically confirmed primary prostate cancer from the Fifth Affiliated Hospital of Zhengzhou University between January 2011 and January 2014. Tumor types and stages were determined by two pathologists. The cases who had not received any chemotherapy or radiotherapy were selected into our study. Total 572 control subjects were randomly selected from individuals who came to undergo a routine health examination during the same period. All the control subjects were found to be without cancers. The controls were matched with one case by age at enrollment (within ±5 years). Demographic and lifestyle characteristics of cases and controls were taken on a predesigned questionnaire. All the patients and controls agreed to sign an informed consent before entering the study.
The collection and use of tumor and blood samples for this study were previously approved by ethnics committee of the Fifth Affiliated Hospital of Zhengzhou University. DNA extraction and genotype analysis: Each subject was asked to provide 5-ml venous blood sample for DNA preparation. 0.5mg/ml EDTA was taken for anticoagulant of blood, and the blood was stored in -20ºC until use. Genomic DNA was extracted from a peripheral blood with TIANamp Blood DNA Kit (Tiangen, Beijing, China) according to the manufacturer's instructions. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed to detect XRCC1 codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) polymorphisms. The primers of XRCC1 codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) were designed using Sequenom Assay Design 3.1 software (Sequenom, San Diego, CA). Briefly PCR was carried out in a final volume of 25 μL containing 50 ng genomic DNA template, 1×PCR buffer with 2 mM MgCl2, 0.5 μM of each primer, 50 μM dNTPs and 0.5 U DNA polymerase. For PCR amplification, the standard program was used as follows: one initial denaturation step at 94°C for 7 minutes, followed by 35 denaturation cycles of 1min at 94°C, 1min of annealing at 60°C, and one minutes of extension at 72°C, followed by a final elongation cycle at 72°C for 10 min. (Arg>His) and 399 (Arg>Gln) gene polymorphisms and risk of prostate cancer were assessed by conditional logistic regression with the adjustment for potential confounding factors, and the assessed results were expressed with odds ratio (OR) and 95% confidence intervals (CI). Gene-environmental interaction was evaluated by conditional logistic regression. All P-values were two sided, and statistically significance was set at P-value less than 0.05. All statistical analyses were performed using the STATA version 10.0 software.
RESULTS
The demographic and clinical characteristics of included prostate cancer cases and controls are shown in Table- 
DISCUSSION
In this case-control study, we investigated that the role of XRCC1 codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) polymorphism in the risk of prostate cancer, and the gene-environmental interaction on the development of prostate cancer.
Haipeng Zhu et al. Since there is increasing evidence that genetic variation leads to different DNA repair capacities in the human population, several common polymorphisms in BER pathway can play a role in individuals' genetic susceptibility to cancer. 14 Mutations in XRCC1 gene may play a role in decreasing or losing of its DNA repair capacity and confering the variation in susceptibility to diverse malignant tumors among individuals. It is reported that there were more than 300 SNPs in XRCC1 gene, and XRCC1 Arg194Trp and XRCC1 Arg399Gln polymorphisms are the most common studies SNPs. 8, 14 Many studies have indicated that the XRCC1 Arg194Trp polymorphism may influence the development of several kinds of cancer, including glioma and thyroid cancer, 15, 16 but several meta-analysis showed that no association between XRCC1 Arg194Trp polymorphism and risk of head and neck cancer, hepatocellular carcinoma, lung cancer and head and neck cancer. [16] [17] [18] For prostate cancer, several epidemiological studies investigated the association between XRCC1 polymorphisms and susceptibility to prostate cancer. [19] [20] [21] However, the results of these studies are inconsistent. Xu et al. investigate the correlation between XRCC1 codons 194 (Arg>Trp), 280 (Arg>His) and 399 (Arg>Gln) polymorphisms and prostate cancer risk, and they suggested that XRCC1 Arg280His and Arg399Gln variant genotypes have a role in the development of prostate cancer, and have interaction with heavy tobacco smoking. 19 Another study conducted in a north Indian population, and reported that Gln/Gln genotype of XRCC1 codons 399 (Arg>Gln) greatly increased the risk of prostate cancer. 21 However, Dhillon et al. did not find significant association between XRCC1 polymorphisms and prostate cancer risk. 20 Recent two meta-analysis showed that XRCC1 codons 194 (Arg>Trp) and 399 (Arg>Gln) were not significantly associated with risk of prostate cancer. 22, 23 The discrepancies of the finding from previous epidemiological studies could be elucidate by differences in populations, source of prostate cancer patients or cancers, lifestyles of populations, sample size study design and also by chance.
Our study found that XRCC1 194 (Arg>Trp) polymorphism has interaction with tobacco smoking, alcohol drinking and family history of cancer, which indicated that a significantly gene-environment interaction was shown in the risk of prostate cancer. A previous study showed that XRCC1 Arg399Gln variant genotypes was associated with a heavy increased risk of prostate cancer in heavy smokers, 19 and their results are in line with ours.
There were three limitations in this study. First, the cases and controls were selected from one hospital, and thus selection bias may be existed in this study. Second, we only investigated association between XRCC1 and risk of prostate cancer, and other DNA repaired genes may have interaction with XRCC1. Third, the sample size of this study is relatively small, and this small sample size may limit the statistical power to find the difference between groups. Therefore, large sample size DNA repaired genes & prostate cancer 
